Log in

ISCO International Stem Cell CORP OTC · United States

International Stem Cell CORP (ISCO) news

Latest International Stem Cell CORP news

  1. Company Updates

    International Stem Cell agrees to sell Lifeline Cell Technology for $25.0 million

    The buyer is American Type Culture Collection, Inc., and the company expects the sale to close in the third fiscal quarter of 2026, subject to closing conditions.

International Stem Cell CORP annual financials

LineFY2025FY2024
Research and development$684,000$657,000
Net income (loss)-$418,000-$209,000
Cash from operations$8,000$13,000
Cash and equivalents$993,000$1.2 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about International Stem Cell CORP

What is the ticker symbol of International Stem Cell CORP?

International Stem Cell CORP trades under the ticker ISCO on OTC.

Where is International Stem Cell CORP listed?

International Stem Cell CORP is listed on OTC.

Which country or territory is International Stem Cell CORP listed under?

Our directory records International Stem Cell CORP under United States.

Does aibio.space cover International Stem Cell CORP?

aibio.space lists International Stem Cell CORP among 2,820 public biotech companies and publishes its news here as stories appear.

Is International Stem Cell CORP profitable?

International Stem Cell CORP reported a net loss of $418,000 for the fiscal year ended Dec 31, 2025, and generated $8,000 of cash from operations, per its annual report to the SEC.

How much does International Stem Cell CORP spend on research and development?

$684,000 in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does International Stem Cell CORP have?

$1.1 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest International Stem Cell CORP (ISCO) stock news?

Our latest story on International Stem Cell CORP, dated Sep 1, 2026: "International Stem Cell completes sale of Lifeline Cell Technology to ATCC". The sale closed September 1, 2026 at an adjusted price of $25,250,000, and the company filed unaudited pro forma statements showing its effect. Source.

Is International Stem Cell CORP being acquired or merging?

Our latest merger story, dated Sep 1, 2026: "International Stem Cell completes sale of Lifeline Cell Technology to ATCC". The sale closed September 1, 2026 at an adjusted price of $25,250,000, and the company filed unaudited pro forma statements showing its effect. Source.

How can I follow International Stem Cell CORP (ISCO) news?

Press Follow on this page to add International Stem Cell CORP to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming International Stem Cell CORP so far, in Company Updates, Mergers.

Investor discussion: International Stem Cell CORP

Members talk about International Stem Cell CORP (ISCO). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at International Stem Cell CORP, newest first. Each line links the filing it comes from.

  1. Mergers

    Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:ISCO on TradingView.

Listing details

International Stem Cell CORP is a public biotech or pharmaceutical company listed on OTC under the ticker ISCO, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
International Stem Cell CORP
Ticker
ISCO
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.